Pay in 4 interest-free payments of $5.56 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
In all three studies, adults with obesity or overweight with at least one weight-related comorbidity were randomly assigned to once-weekly subcutaneous tirzepatide or placebo for 72 weeks
The ATTAIN-MAINTAIN trial demonstrated that patients switching from tirzepatide to orforglipron maintained most of their weight loss, with modest regain of approximately 5 kg on average
Clinical research and our clients experiences show improvements in blood sugar levels, even for those without diabetes
#EmployeeBenefits #GLP1 #BenefitsStrategy #HRLeadership To view or add a comment, sign in Millions of people are on GLP-1s
US$ 28.20
US$ 21.44
US$ 26.64
US$ 21.87
US$ 22.72
US$ 22.71
US$ 21.57
US$ 23.66
US$ 27.35
US$ 27.84
